Cancer and Bone Society

ABSTRACTs & POSTERS

Abstract submissions for CABS 2024 are now closed. Abstract notifications for poster/oral presentations, awards, and travel awards have been sent to all abstract submitters. If you have not received a notification email, please contact Julie Rhoades at julie.rhoades@vumc.org.

There will be a dedicated poster session at the CABS conference and opportunities for oral presentations.

Conference information, HOTELS, & Logistics

The 2024 CABS conference will take place in person July 12-14, 2024 at the University of Sheffield in Sheffield, England. The CABS conference will begin on the last day of the Bone Research Society (BRS) conference, taking place July 10-12, 2024 at the University of Sheffield. CABS conference sessions will be held on the University of Sheffield campus in Halifax Hall and the Edge building. Attendees are encouraged to register for both conferences and discounts will be available.

The July 12 and July 14 CABS sessions will be held at Halifax Hall (July 13 sessions will be at The Edge, a short walk away), so if you stay at this hotel you will be onsite for those days. The Jonas Hotel is a few minutes walk from the Halifax Hotel.

Hotel rooms are held at the Halifax Hall Hotel and the Jonas Hotel for the BRS and CABS. To secure accommodations within the room block, please use the link below, or call/email the hotel and let them know you are in the BRS and CABS Annual Meeting room block and which nights you would like to book (there is one room block name for both conferences).

Halifax Hall Hotel: All rooms in the Halifax Hall Hotel room block are now full during the CABS conference dates.

Jonas Hotel: Please use the link below to book your accommodations. You will need to select your dates of stay and number of rooms. It will show no rooms available, but if you enter the code KX78987 (under Promotions/Add Group Code) and click update, it will bring up rooms from your allocation. Please note, the rooms are small and will be most comfortable with single occupancy.

Link to book: https://www.jonashotel.co.uk/ (enter KX78987 under Group Code on the second page)

Rates: The rate is £55.00 per night, which includes a hot drink and pastry from Reception in the morning.

Contact Information: Call the Jonas hotel at 0114 222 8816 or email at hello@jonashotel.co.uk.

Scientific program

***DRAFT PROGRAM***

Friday, July 12, 2024 

Registration desk open 8:00am - 11:00am

Halifax Hotel

***For those attending the Bone Research Society (BRS) conference, there is a cancer and bone session from 9:00 - 10:30am on July 12. CABS will therefore begin mid-morning to accommodate attendees registered for BRS and CABS.***

10:00am – 11:00am Light Networking Breakfast

11:00am – 11:10am Welcome and Opening Comments, Rachelle Johnson, PhD, CABS President, and Janet Brown, MSc, MD, FRCP, CABS President-Elect and onsite organizer

11:10am - 12:25pm Plenary symposium: Clinical management of bone metastases: History and Where We're Headed

11:10am -11:35am Bone targeted therapy for metastatic bone disease - Past, present and future, Rob Coleman, MBBS, MD, FRCP, FRCPE, University of Sheffield, Sheffield, England

11:35am - 12:00pm Updates in immunotherapy and novel drugs in the clinical management of multiple myeloma, Christopher Parrish, MD, Leeds Teaching Hospitals NHS Trust, Leeds, England

12:00pm - 12:25pm Anti-resorptives in bone metastatic disease - insight from pre-clinical studies to optimise their clinical utility, Michelle McDonald, PhD, The University of Sydney, Sydney, Australia

12:25pm – 1:40pm LUNCH

Clinical Lunch Session

12:35pm - 1:35pm Clinical breakthroughs in the treatment of bone cancer and metastatic disease

12:35pm - 12:55pm Renal bone metastases: Clinical features and impact of recent treatment advances, Janet Brown, BMedSci, MB BS, MSc, MD, FRCP, University of Sheffield, Sheffield, England

12:55pm - 1:15pm Stereotactic Radiotherapy for Bone metastases, Peter Dickinson, MD, Leeds Teaching Hospitals NHS Trust, Leeds, England

1:15pm - 1:35pm Clinical research in osteosarcoma, Robin Young, MBChB MRCP MSc PhD, Sheffield Teaching Hospital, Sheffield, England

1:40pm – 2:50pm Molecular Advances in the Bone Metastatic Niche

1:40pm – 2:05pm Roles of small noncoding RNAs in the bone metastatic niche, and potential implications for cancer prognosis and targeted therapies, Philippe Clézardin, PhD, DSc,  INSERM, Lyon, France

2:05pm - 2:30pm Microenvironmental signals driving breast cancer metastatic colonisation in the bone, Robert Clarke, PhD, Manchester Breast Centre, Manchester, England

2:30pm - 2:40pm Adiposity disrupts the dormant niche in multiple myeloma, Young-Eun Park, PhD, University of Oxford, Oxford, England

2:40pm – 2:50pm TGF-β signaling and Gli2 activation mediate chemoresistance and osteolysis in bone-tropic breast cancer, Jade Miller, Vanderbilt University, Nashville, TN, USA

2:50pm - 3:00pm Presentation of the CABS 2023 Distinguished Service Award

3:00pm - 3:25pm BREAK, Coffee, tea, and refreshments

3:25pm - 4:25pm Treating Bone Metastases: Meet the Doctor Clinical Panel

4:25pm – 4:50pm BREAK, Coffee, tea, and refreshments

4:50pm - 5:50pm Lightning Talks, High Scoring Abstract Winners

4:50pm – 4:55pm The bone anabolic agent losartan mitigates bone loss in breast cancer-induced bone disease in vivo, Jacky Wong, University of Sheffield, Sheffield, England

4:55pm - 5:00pm Dual inhibitory role of miR-24-2-5p in early stages of breast cancer bone metastasis formation, Margherita Puppo, PhD, INSERM, Lyon, France

5:00pm – 5:05pm TGFBI-mediates osteocyte apoptosis and gap junction failure in renal cell carcinoma bone metastasis, Robert Satcher, MD, PhD, FAOA, FAAOS, FAIMBE, MD Anderson, Houston, TX, USA

5:05pm - 5:10pm Addition of ATM inhibitors to radium223 treatment reduces PC3 castrate resistant prostate cancer bone metastases in vivo, Diane Lefley, University of Sheffield, Sheffield, England

5:10pm - 5:15pm Dissecting the reciprocal effects of the aging bone stroma on multiple myeloma, Karl Nyman, Moffitt Cancer Center, Tampa, Florida, USA

5:15pm - 5:20pm Bone Loss and Muscle Weakness in Myeloma-Bearing Mice Treated with Proteasome Inhibitor is Partially Attenuated with Low Intensity Vibration, Gabriel Pagnotti, PhD, MD Anderson, Houston, TX, USA

5:20pm - 5:25pm An adaptable 3D model of myeloma cell dormancy for pre-clinical drug screening, Alexandria Sprules, University of Sheffield, Sheffield, England

5:25pm - 5:30pm Regulation and targeting of G6PD in the prostate-cancer bone microenvironment, Renee Ormsby, PhD, University of Oxford, Oxford, England

5:30pm - 5:35pm Regulation of the breast tumor suppressor LIFR gene transcription by carboxy-terminal PTHrP domain, Jeremy Kane, Vanderbilt University, Nashville, TN, USA

5:35pm - 5:40pm Molecular profiling of the role of prostate cancer derived exosomes as mediators of metastatic spread to bone, Steven Wood, MD, University of Sheffield, Sheffield, England

5:40pm – 5:45pm Analysis of synergistic effects of DMAB and ICI in metastatic bone patients, Emmanuel Massy, Hospices Civils de Lyon, Lyon, France

5:45pm – 5:50pm Glycosylation enzyme ST6GAL1 – a novel target for prostate cancer bone metastasis, Ning Wang, PhD, FHEA, MRes, MSc, Leicester, England

6:00pm - 8:00pm Poster Session and Drinks Reception (at The Edge)

Saturday, July 13, 2024 

Registration desk open 7:45am – 9:00am

The Edge

8:15am - 9:00am Light Networking Breakfast

9:00am - 10:15am Plenary Symposium: Updates on therapeutic responses in bone metastasis and fracture risk

9:00am - 9:25am Fracture risk in the adjuvant setting - Who is at risk?, Peyman Hadji, MD, Frankfurt Hormone and Osteoporsis Center, Frankfurt, Germany

9:25am - 9:50am Metastatic Cancer-Bone Interactions and Therapeutic Responses in Clinically Relevant Murine Models and in Human Patients, Francis Lee, MD, PhD, Hon MBA, Yale School of Medicine, New Haven, CT

9:50am - 10:15am Assessment of the biomechanical properties of metastatic vertebrae with computational models, Enrico Dall’Ara, PhD

10:15am – 11:00am BREAK, Coffee, tea, and refreshments

11:00am - 12:10pm Immuno-oncology and the Bone Microenvironment

11:00am - 11:25am The efficacy of a oncolytic SLAMF7-adenovirus to treat myeloma, Shelly Lawson, PhD, FHEA, University of Sheffield, Sheffield, England

11:25am - 11:50pm Driving γδ CAR-T into the bone metastatic prostate cancer microenvironment, Conor Lynch, PhD, Moffitt Cancer Center, Tampa, Florida, USA

11:50pm - 12:00pm High Glutamate levels in multiple myeloma patients affect Osteoclast differentiation: a possible novel therapeutic target for myeloma bone disease, Nicola Giuliani, MD, PhD, University of Parma, Parma, Italy *Outstanding Abstract Award

12:00pm - 12:10pm Stromal Cell Senescence Induced by Dnmt3a-Mutant Hematopoietic Cells is a Targetable Mechanism Driving Clonal Hematopoiesis and Initiation of Hematologic Malignancy, Jayna Mistry, PhD, The Jackson Laboratory, Bar Harbor, ME, USA

12:10pm - 1:45pm LUNCH and Interactive Discussion / Debate: All conference attendees are invited to debate, discuss, and briefly present critical topics in small groups

12:10pm - 12:25pm Collect lunch

12:25pm - 12:30pm Group Guidelines and Instructions

12:30pm – 1:30pm Topic Discussions and Presentations

1:45pm - 2:30pm Plenary Oral Presentations, Session I (Plenary orals indicate the highest scoring abstracts)

1:45pm - 2:00pm Breast cancer cells rely on mitochondrial respiration to form bone metastases, Karina Geurtzen, PhD, KU Leuven, Leuven, Belgium

2:00pm – 2:15pm High cholesterol promotes bortezomib resistance in myeloma cells and increased tumour burden in vivo, Beatriz Gamez, PhD, University of Oxford, Oxford, England

2:15pm - 2:30pm PD-1 blockade induces musculoskeletal toxicities in a breast cancer bone metastatic model, Gwenyth Joseph, Vanderbilt University, Nashville, TN, USA

2:30pm - 2:45pm BREAK, Coffee, tea, and refreshments

2:45pm - 4:45pm Networking Trivia

4:45pm - 5:00pm BREAK

5:00pm - 8:00pm Conference Dinner

Sunday, July 14, 2024

Registration desk open 7:45am – 9:00am

The Edge

8:15am - 9:00am Light Networking Breakfast

9:00am - 10:25am Spatial Profiling of the Bone Metastatic Niche

9:00am - 9:25am Spatial imaging of bone metastasis and regeneration, Ralph Müller, PhD, ETH Zurich, Zurich, Switzerland

9:25am - 9:50am Heterogeneous nerve remodeling patterns across bone compartments in multiple myeloma, Marta Diaz del Castillo, PhD, University of Aarhus, Aarhus, Denmark

9:50am - 10:15am Applying engineered bone marrow models to study myeloma-microenvironment interactions, Abdullah Khan, PhD, University of Oxford, Oxford, England

10:15am - 10:25am Single cell sequencing reveals a novel osteoblast-derived cell population supporting breast cancer bone metastasis, Jennifer Zarrer, PhD, Ludwig Maximilian University Klinikum, Munich, Germany

10:25am - 10:55am BREAK, Coffee, tea, and refreshments

10:55am - 11:55am Plenary Oral Presentations, Session II (Plenary orals indicate the highest scoring abstracts)

10:55am - 11:10am Spatial transcriptomic profiling of the immune landscape in multiple myeloma, Ryan Bishop, PhD, Moffitt Cancer Center, Tampa, FL, USA

11:10am - 11:25am Dovitinib Mitigated Prostate Cancer Bone Metastases via Inhibiting the FGF Pathway, Xinhai Wan, MD, PhD, MD Anderson, Houston, TX, USA

11:25am - 11:40am Altered osteocyte lacunae morphology and canalicular network organisation in a preclinical model of myeloma bone disease, Rebecca Andrews, MRCP(UK), PGCert Clin Res, MBChB, University of Sheffield, Sheffield, England

11:40am - 11:55am Combining Anakinra with Paclitaxel and Zoledronic acid reduces metastatic outgrowth of triple-negative breast cancer cells in mouse bone and soft tissues, Jiabao Zhou, PhD, University of Sheffield, Sheffield, England

11:55am – 12:35pm Meet the Professor Sessions

12:35pm – 1:45pm LUNCH* (in Halifax Hall)

*CABS Board Meeting - Board members please get lunch and proceed to TBD.

1:45pm - 2:30pm Plenary Oral Presentations, Session III (Plenary orals indicate the highest scoring abstracts)

1:45pm – 2:00pm Single-cell RNA sequencing identifies common components of the dormant tumour cell niche in bone and other metastatic sites, James Smith, PhD, Garvan Institute of Medical Research, Sydney, Australia

2:00pm - 2:15pm 2:00pm - 2:15pm A Dual Action Bone-Targeted Therapy to Combat Multiple Myeloma, Eradicate Dormant Cells, and Improve Bone Health, Hayley Sabol, University of Arkansas Medical School, Little Rock, AR, USA

2:15pm - 2:30pm cAMP-mediated acid sensing by tumor cells promotes immunosuppressive cytokine production and tumor progression, Kaylee O’Donnell, Washington University in St. Louis, St. Louis, MO, USA

2:30pm – 3:00pm BREAK, Coffee, tea, and refreshments

3:00pm – 4:15pm Plenary Symposium: Tumor Dormancy, Senescence, and the Inflammatory Bone Microenvironment

3:00pm - 3:25pm Therapy induced senescence drives myeloid plasticity in multiple myeloma, Megan Weivoda, PhD, Mayo Clinic, Rochester, MN, USA

3:25pm - 3:50pm Targeting dormant cancer cells and the bone microenvironment in multiple myeloma, Alanna (Leni) Green, PhD, University of Sheffield, Sheffield, England

3:50pm - 4:15pm Stromal-immune interactions driving bone marrow inflammation in multiple myeloma, Tom Cupedo, PhD, Erasmus MC, Rotterdam, Netherlands

4:15pm – 4:30pm Closing Remarks

4:30pm Adjourn